ABSTRACT
<p><b>OBJECTIVE</b>To establish DNA microarrays-based microRNA (miRNA) expression profiles of squamous cell carcinoma of larynx, using archived formalin-fixed paraffin-embedded tissue blocks, and to screen out and identify the differentially expressed miRNAs associated with the biological characteristics of this malignant disease.</p><p><b>METHODS</b>Total RNA was prepared from the formalin-fixed paraffin-embedded tissue blocks. After quality identification and fluorescent labeling, the RNA samples were hybridized with the Agilent human miRNA microarrays which contains 723 probes for human miRNAs. The data was processed with the softwares GeneSpring GX and R-Project.</p><p><b>RESULTS</b>From the formalin-fixed paraffin-embedded tumor blocks collected, 24 RNA samples were obtained with the quality accorded to the requirement of miRNA microarray analysis, and both the hybridization and consequent data processing were accomplished. A total of 319 miRNAs were identified and among them 96 were detected in all the 24 formalin-fixed paraffin-embedded blocks of laryngeal carcinoma; and 5 differentially expressed miRNAs (false discovery rate < 0.05) were found to be associated significantly with the lymphatic metastasis of laryngeal squamous cell carcinoma (P < 0.05), including miR-23a(*), miR-28-5p, miR-15a, miR-16 and miR-425.</p><p><b>CONCLUSIONS</b>Histopathological archives of well-annotated formalin-fixed paraffin-embedded tissue specimens are the valuable resources for miRNA study including to collect RNA samples for miRNA microarray analysis. A panel of differentially expressed miRNAs (miR-23a(*), miR-28-5p, miR-15a, miR-16 and miR-425) derived from the miRNA expression profile may serve as the potential molecular biomarkers for the prediction of metastasis development in laryngeal squamous cell carcinoma.</p>
Subject(s)
Humans , Carcinoma, Squamous Cell , Genetics , Metabolism , Pathology , Gene Expression Profiling , Laryngeal Neoplasms , Genetics , Metabolism , Pathology , Lymphatic Metastasis , MicroRNAs , Metabolism , Oligonucleotide Array Sequence Analysis , Methods , Paraffin EmbeddingABSTRACT
<p><b>OBJECTIVE</b>To evaluate the value of application of cellular protein markers stained by immunocytochemistry in combination with ThinPrep bronchial brush cytology in classification of lung cancer subtypes.</p><p><b>METHODS</b>Remaining bronchial brush cytology samples from 206 lung cancer patients with positive cytological diagnosis and 45 fine needle aspiration samples of resected lung carcinomas were collected. The expressions of CK10/13, CK7, CK18, CD56 and SYN in those samples were detected by immunocytochemistry (ICC) using corresponding antibodies.</p><p><b>RESULTS</b>The sensitivity and specificity of CK10/13 were 94.7% and 72.0%, respectively, in diagnosis of squamous cell carcinoma. The sensitivity and specificity of CK7 were 98.6% and 61.5%, and those of CK18 were 98.6% and 37.5%, respectively, in diagnosis of adenocarcinoma. The sensitivity and specificity of CD56 were 86.3% and 82.9%, and those of SYN were 81.6% and 93.5%, respectively, in diagnosis of small cell lung cancer. No significant difference was found in the expressions of CK10/13, CK7 and CK18 protein markers among differently differentiated lung squamous cell carcinomas and adenocarcinomas (P > 0.05). The classification rate of cytology in combination with ICC in differential diagnosis for 44 cases of unclassified lung cancer reached 90.0% for squamous cell carcinoma, 96.3% for adenocarcinoma, and 100.0% for small cell lung carcinoma.</p><p><b>CONCLUSION</b>Application of cellular protein markers in combination with ThinPrep bronchial brush cytology is helpful to improve the differential diagnosis of lung cancer subtypes, and may become a supplementary diagnostic method in subclassification of lung cancer.</p>
Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Adenocarcinoma , Diagnosis , Metabolism , Biomarkers, Tumor , Metabolism , Biopsy, Fine-Needle , Bronchi , Pathology , Bronchoscopy , CD56 Antigen , Metabolism , Carcinoma, Squamous Cell , Diagnosis , Metabolism , Cytodiagnosis , Methods , Cytological Techniques , Diagnosis, Differential , Immunohistochemistry , Keratin-13 , Metabolism , Keratin-18 , Metabolism , Keratin-7 , Metabolism , Lung Neoplasms , Classification , Diagnosis , Metabolism , Sensitivity and Specificity , Small Cell Lung Carcinoma , Diagnosis , Metabolism , Synaptophysin , MetabolismABSTRACT
<p><b>OBJECTIVE</b>To study the expression of targeting protein for Xklp2 (TPX2) and its significance in squamous cell carcinoma (SCC) of the lung.</p><p><b>METHOD</b>Two SCC cell lines and 4 immortalized bronchial epithelial cell lines (as a precancerous model) were examined by Western blot for TPX2 expression. Reverse transcription-polymerase chain reaction analysis for TPX2 was also performed using tumor tissues from 21 patients with SCC of the lung. The expression of TPX2 was studied by immunohistochemistry (using tissue microarray) on paraffin-embedded sections of pulmonary SCC and corresponding precancerous lesions from a group of 319 patients.</p><p><b>RESULTS</b>TPX2 was variably expressed in all the cell lines studied. Compared with matched controls using normal lung tissue, high level of TPX2 mRNA was detected in 16 of the 21 SCC tumor tissue samples analyzed. Immunohistochemical study showed that TPX2 was mainly present in tumor tissues but not in normal controls. The expression of TPX2 correlated with tumor grade, stage and nodal status. As for precancerous lesions, the level of TPX2 was also increased, in accordance with the degree of dysplasia.</p><p><b>CONCLUSIONS</b>Expression of TPX2 may play a role in carcinogenesis of bronchial epithelium and tumor progression of pulmonary SCC. It may also represent a potential biomarker for surveillance of SCC of lung.</p>
Subject(s)
Humans , Blotting, Western , Carcinoma, Squamous Cell , Genetics , Metabolism , Pathology , Cell Cycle Proteins , Genetics , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Immunohistochemistry , Lung , Metabolism , Pathology , Lung Neoplasms , Genetics , Metabolism , Pathology , Microtubule-Associated Proteins , Genetics , Nuclear Proteins , Genetics , Precancerous Conditions , Genetics , Metabolism , Pathology , RNA, Messenger , Genetics , Metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tissue Array AnalysisABSTRACT
<p><b>OBJECTIVE</b>To evaluate aberrant methylation of the p16 promoter as a useful biomarker of lung cancer.</p><p><b>METHODS</b>A modified methylation-specific semi-nested PCR was performed to detect p16 hypermethylation in the matched samples of tumor tissue, blood plasma and sputum derived from 51 cases of lung cancer patients.</p><p><b>RESULTS</b>Hypermethylation of p16 promoter was demonstrated in 84.3% of the tumor tissues, 70.6% of the blood plasma and 76.5% of the sputum specimens, respectively. Only the patients whose tumor tissues had p16 hypermethylation exhibited aberrant methylation in their plasma and/or sputum specimens. Combining with cytological examination, 92.2% of the patients with lung cancer could be detected by p16 hypermethylation assay in both sputum and plasma samples.</p><p><b>CONCLUSION</b>The results indicate that p16 hypermethylation in plasma and sputum identified by semi-nested PCR is a biomarker of lung cancer which can be useful as an auxillary diagnostic parameter.</p>